118 results about "Liver lipid" patented technology

The invention discloses Lachnum sp., an extracellular polysaccharide thereof and application of the extracellular polysaccharide in preparing lipid-lowering liver-favoring medicaments. The invention is characterized in that a Lachnum sp. strain with the collection number of CCTCC (China Center for Type Culture Collection) No: M 2011196 is activated and inoculated to a fermentation culture medium, thus preparing the Lachnum sp. extracellular polysaccharide. When the administration dosage is 150-300 mg / (kg bw), the prepared Lachnum sp. extracellular polysaccharide can significantly lower the levels of serum lipid and liver lipid and atherosis index of high-lipid mice, and increase the level of serum high-density lipoprotein cholesterol and the excretion amount of feces lipid. When the administration dosage is 75-300 mg / (kg bw), the prepared Lachnum sp. extracellular polysaccharide can significantly lower the activity of serum aminotransferase and malondialdehyde content in liver tissues of high-lipid mice, and increase the activity of sudismase in the liver tissues. The prepared Lachnum sp. extracellular polysaccharide has obvious effects of lowering blood lipid, lowering liver lipid, and treating hepatic injury and dysfunction caused by high lipid, has no toxic or side effects, and can be prepared into tablets or capsules for clinical application.

The invention discloses functional food with the effects of protecting the liver and improving eyesight. The functional food is made from 40-60 parts by weight of alga polyphenol, 30-50 parts by weight of fucoxanthin, 10-20 parts by weight of astaxanthin, 10-20 parts by weight of taurine, 0.1-1 part by weight of vitamin C and 0.1-1 part by weight of vitamin E through the process of blending, sterilizing, pelletizing, tabletting and packaging. The functional food can be made into capsules or tablets or instant powder or oral liquid or drink, and has the remarkable effects of regulating liver lipid metabolism and improving eyesight.

The invention relates to the technical field of wine brewing, in particular relates to liver protecting liquor and a preparation method thereof. Calendula, silybum marianum, Cynara scolymus, flower ofkudzuvine, root of kudzu vine, parsley and grains are fermented together, the calendula can fully play the effect of alleviating alcohol poisoning, tonifying liver, reducing total liver lipid, cholesterol and triglyceride; the silybum marianum activates the regeneration of liver proteins, restores the activity of damaged liver cells, and reduces damage of toxins to the liver; the Cynara scolymusincreases liver viability to promote elimination of the toxins in the liver and promotes the regeneration of the liver cells; the flower of kudzuvine is combined to play the role of activating spleen,relieving alcoholism, and stop bleeding; the root of kudzu vine has the effects of relieving muscles, clearing heat, engendering liquid and allaying thirst, the parsley has the effects of calming theliver, reducing blood pressure, tranquilizing and allaying excitement, and the like, alcohol damage to the liver is reduced, nutrient content of the wine is increased, and finally the liver protecting liquor has the effects of dilating blood vessels, lowering blood pressure, removing lipids in the blood, protecting liver, preventing arteriosclerosis and protecting cardiovascular system is obtained.

The present invention provides a method to prepare polysaccharides from Ganoderma lucidum. The prepared polysaccharides can reduce liver weight and liver lipid content in humans and animals. The prepared polysaccharides can therefore be used to prevent and treat fatty liver disease.

The invention discloses application of nuclear factor kappa B arrestin 3 combined with A20 in preparation of drugs for treating fatty liver and related diseases, and belongs to new use of ABIN3. An L02 cell line, an ABIN3 over-expressing L02 cell line, a mouse primary hepatocyte cell, and an ABIN3 over-expressing mouse primary hepatocyte cell are used as an experimental object, and a fatty liver cell model is induced through combination of palmitic acid and oleic acid. Oil red O staining results show that compared with L02 cells, an area of red fat droplets in ABIN3 over-expressing L02 cells is significantly reduced under combined stimulation of the palmitic acid and the oleic acid at the same concentration. A same trend of the oil red O staining results is also observed in the ABIN3 over-expressing mouse primary hepatocyte cell, indicating that ABIN3 overexpression significantly inhibits lipid accumulation in fatty liver cells induced by the palmitic acid and the oleic acid. Therefore, ABIN3 has the functions of inhibiting liver lipid accumulation and protecting liver.